Three provinces to study 2-dose HPV vaccine

Eggertson, Laura
August 2007
CMAJ: Canadian Medical Association Journal;8/28/2007, Vol. 177 Issue 5, p444
Academic Journal
The article reports that a clinical trial to study the safety and effectiveness of giving younger girls 2 doses of a new vaccine against human papillomavirus (HPV) instead of the current 3-dose regimen, will be studied by the provinces of British Columbia, Quebec, and Nova Scotia in Canada. The new vaccine called Gardasil, is intended to prevent some of the strains of cervical cancer arising from HPV. Clinical researchers are hoping to establish whether 2 doses of the new vaccine against HPV are as effective as the current more expensive 3-dose regimen. According to Simon Dobson, principal investigator, there are implications that a 2-dose schedule saves a third of the price. He says, it would also reduce the administrative costs if nurses administered it during the school year.


Related Articles

  • Fewer Than Three Doses of Cervical Cancer Vaccine Effective.  // JNCI: Journal of the National Cancer Institute;Oct2011, Vol. 103 Issue 19, pNP 

    The article reveals that less than three doses of the human papillomavirus (HPV) vaccine Cervarix could be just as effective as the standard three-dose regimen in preventive measures against cervical cancer, according to a study published on September 9, 2011 in the "Journal of the National...

  • HPV Vaccines--Prophylactic, Not Therapeutic. Markowitz, Lauri E. // JAMA: Journal of the American Medical Association;8/15/2007, Vol. 298 Issue 7, p805 

    This editorial comments on a study in this issue which sought to see if human papillomavirus vaccines (HPV) could clear the viral load in patients who already had the disease. The author says because the study showed the vaccine had no effect following infection, it makes it more important to...

  • HPV vaccination: why education is the key to ensuring it is a public health success. Gehring, Alison; Donaldson, Caitlyn // Education & Health;2008, Vol. 26 Issue 4, p77 

    The article discusses Great Britain's Human Papillomavirus (HPV) vaccination programme. The article notes that most cases of cervical cancer are attributed to HPV, with 3000 cases diagnosed and over 1000 deaths per year. Great Britain held its first pilot programme in September 2008, providing...

  • Knowledge and Perceptions of HPV and the HPV Vaccine among Pre-adolescent Girls and Their Guardians in Georgetown, Guyana. Tyrell, E.; Ramsammy-Boyce, K. // West Indian Medical Journal;Jan2015, Vol. 64 Issue 1, p43 

    Objectives: To examine the knowledge and perceptions of 11-year old girls and their guardians toward the human papillomavirus (HPV), HPV (mandatory) vaccination and cervical cancer and to determine their main sources of health information. Methods: A cross-sectional study was done by...

  • A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool. Hutubessy, Raymond; Levin, Ann; Wang, Susan; Morgan, Winthrop; Ally, Mariam; John, Theopista; Broutet, Nathalie // BMC Medicine;2012, Vol. 10 Issue 1, p136 

    Background: The purpose, methods, data sources and assumptions behind the World Health Organization (WHO) Cervical Cancer Prevention and Control Costing (C4P) tool that was developed to assist low- and middle-income countries (LMICs) with planning and costing their nationwide human...

  • What to Do About HPV? Kotz, Deborah // U.S. News & World Report;10/29/2007, Vol. 143 Issue 15, p53 

    The article discusses the debate over inoculating young girls with the human papillomavirus (HPV) vaccine. The vaccine protects against four types of HPV, two of which cause genital warts and two of which are responsible for up to 70 percent of cervical cancers. The concern over giving the...

  • Raising Expectations For Subunit Vaccine. Schiller, John T.; Lowy, Douglas R. // Journal of Infectious Diseases;May2015, Vol. 211 Issue 9, p1373 

    Multidose regimens are recommended for all prophylactic subunit vaccines. Recent findings from clinical trials of an human papillomavirus virus-like particle vaccine suggest that it may be possible to develop effective single-dose subunit vaccines. The broad implications of these findings are...

  • Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis. Laprise, Jean-François; Markowitz, Lauri E.; Chesson, Harrell W.; Drolet, Mélanie; Brisson, Marc // Journal of Infectious Diseases;9/1/2016, Vol. 214 Issue 5, p685 

    A recent clinical trial using the 9-valent human papillomavirus virus (HPV) vaccine has shown that antibody responses after 2 doses are noninferior to those after 3 doses, suggesting that 2 and 3 doses may have comparable vaccine efficacy. We used an individual-based transmission-dynamic model...

  • The Case for Conducting a Randomized Clinical Trial to Assess the Eficacy of a Single Dose of Prophylactic HPV Vaccines Among Adolescents. Kreimer, Aimée R.; Sherman, Mark E.; Sahasrabuddhe, Vikrant V.; Safaeian, Mahboobeh // JNCI: Journal of the National Cancer Institute;3/11/2015, Vol. 107 Issue 3, p1 

    The article discusses comments on the randomized trial for assessing the single-dose prophpylactic human papillomavirus (HPV) vaccine and its efficacy for adolescent patients. Topics covered include the strong evidence of single-dose efficacy in bivalent vaccine and the need for developing...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics